Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,630 active trials11 approved drugs139 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,171 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07241091 | SurgiPerito Trial: High-Purity Type-I Collagen for Peritoneal Reconstruction After Cytoreductive Surgery | completed | N/A | 60 | Adichunchanagiri Institute of Medical Sciences, B G NagaraOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT02122185 | Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 111 | University of ChicagoOTHER | 1 | Mar 27, 2026 |
| clinicaltrials |
| NCT02865837 | Effect of Bladder Distension on Dosimetry in Brachytherapy of Cervical Cancer(VESICOL) | completed | N/A | 22 | Institut de Cancérologie de LorraineOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03617679 | Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer | completed | Phase 2 | 79 | University of Colorado, DenverOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04557423 | Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening | completed | N/A | 797 | Fox Chase Cancer CenterOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT06662435 | GYNecologic Cancer-Related COGnitive Impairment(GYNCOG) | completed | N/A | 60 | Northwestern UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT04539327 | Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study | completed | — | 51 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04814108 | A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma | completed | Phase 2 | 92 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT05198804 | A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 117 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT01303094 | Continuing vs Intermittent Trabectedin in Patients With Advanced Soft Tissue Sarcoma(T-DIS) | completed | Phase 2 | 53 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT01247779 | Perioperative Morbidity in Gyneco-oncology According to the Procedure : Coelioscopy Versus Robot-assisted Coelioscopy(ROBO-GYN) | completed | N/A | 386 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT03315351 | Feasibility of Pet-scan at Day 1 of Brachytherapy for Patients With Cervical Cancer(TEP-Curie) | completed | N/A | 14 | Centre Oscar LambretOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04300647 | A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer(SKYSCRAPER-04) | completed | Phase 2 | 172 | Hoffmann-La RocheINDUSTRY | 17 | Mar 12, 2026 | clinicaltrials |
| NCT02867956 | Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer | completed | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03367247 | BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal | completed | N/A | 121 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04341883 | Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer | completed | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05494580 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02858310 | E7 TCR T Cells for Human Papillomavirus-Associated Cancers | completed | Phase 1 / Phase 2 | 224 | National Cancer Institute (NCI)NIH | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04423679 | The Selfie Study- Assessing Novel Markers for Cervical Cancer Screening From Self-collected Samples(SELFIE) | completed | — | 294 | George Washington UniversityOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06184867 | Choices About Genetic Testing And Learning Your Risk With Smart Technology(CATALYST) | completed | N/A | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04024254 | A Study of Serum Folate Levels in Patients Treated With Olaparib | completed | Phase 4 | 10 | Rush University Medical CenterOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05035173 | The LYSA (Linking You to Support and Advice) Trial(LYSA) | completed | N/A | 200 | University College CorkOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT06624878 | Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer | completed | N/A | 568 | Zhejiang Cancer HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07439328 | ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer | completed | N/A | 30 | Institute of Oncology LjubljanaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04697628 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer(innovaTV 301) | completed | Phase 3 | 502 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Feb 24, 2026 | clinicaltrials |
| NCT06711380 | Patient Ambassador | completed | N/A | 23 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT03005743 | Image Based Brachytherapy in Locally Advanced Cervical Cancers - a Randomized Controlled Trial(COMBAT-Cx) | completed | N/A | 1,050 | Tata Memorial HospitalOTHER_GOV | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04221945 | Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047) | completed | Phase 3 | 1,060 | Merck Sharp & Dohme LLCINDUSTRY | 30 | Feb 20, 2026 | clinicaltrials |
| NCT04806724 | Opening the Conversation Study | completed | N/A | 158 | Oregon State UniversityOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07407179 | Quality of Life and Lymphedema After Surgical Treatment of Gynecological Malignancies | completed | N/A | 40 | Institute of Oncology LjubljanaOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03579394 | Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer(CHRONO) | completed | N/A | 211 | ARCAGY/ GINECO GROUPOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05870787 | iMproving thE DIagnostics And Treatment Of ceRvical Precancer(MEDIATOR) | completed | — | 929 | University of AarhusOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07393633 | Assessing Whole-body Metabolism in Gynecologic Cancers in Response to a Single Chemotherapy Cycle and/ or Immunotherapy | completed | — | 43 | University of Tennessee Graduate School of MedicineOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT02195973 | Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer | completed | Phase 1 | 15 | University of Alabama at BirminghamOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT01113112 | Biobehavioral-Cytokine Interactions in Ovarian Cancer(VEGF) | completed | — | 613 | Susan LutgendorfOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT02749110 | Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General Practitioner(PaCUDAHL-Gé) | completed | N/A | 308 | University Hospital, LilleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03763838 | Acupressure for Fatigue in Ovarian Cancer Survivors | completed | N/A | 171 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03981731 | Management of Perioperative Anxiety by the Cardiac Coherence Technique Coupled With a Hypnosis Session(COHEC) | completed | N/A | 53 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03635567 | Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) | completed | Phase 3 | 617 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Feb 4, 2026 | clinicaltrials |
| NCT03707574 | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study | completed | — | 64 | National Cancer Institute (NCI)NIH | 2 | Feb 4, 2026 | clinicaltrials |
| NCT04457089 | Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer | completed | Early Phase 1 | 18 | Marc GoodmanOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06086665 | The Real World Efficacy and Safety of Niraparib in Korean Women With Primary and Recurrent Epithelial Ovarian Cancer(REFIRM) | completed | — | 850 | Asan Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT06662136 | The Effect of Motivational Interviewing on HPV-DNA Testing | completed | N/A | 90 | Muazez küçükkayaOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07384468 | Ultrasound-Guided Stellate Ganglion Block Plus Propofol for Perimenopausal Insomnia With Anxiety(SGB-PROP-PIA) | completed | N/A | 233 | Xiaochen JiOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT03884101 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)(LEAP-001) | completed | Phase 3 | 842 | Merck Sharp & Dohme LLCINDUSTRY | 22 | Feb 2, 2026 | clinicaltrials |
| NCT07365969 | Risk of Hysterectomy at Time of Myomectomy | completed | — | 293 | Ain Shams UniversityOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT02407509 | Phase I Trial of VS-6766 Alone and in Combination With Everolimus(RAF/MEK) | completed | Phase 1 | 104 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 30, 2026source: clinicaltrials